Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory ...

Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease ...

The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...

Here’s what science actually shows about declining testosterone in young adults, and why treatment is rarely the first answer ...

Combining Rituxan with Mavenclad or Zelboraf upfront can extend remissions safely and should become standard first-line therapy for hairy cell leukemia. Combining Rituxan (rituximab) with Mavenclad ...

After you've finished treatment for follicular lymphoma, your doctor might tell you that your cancer is in remission. It's a big milestone because it means you have few or no signs of cancer in your ...

Extranodal MALT lymphoma: A retrospective survival analysis study from SEER database. Efficacy and safety of oral tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin ...

Rituxan (rituximab) is a type of antibody therapy (biologic) medication that may be used with or without chemotherapy. It destroys or helps your body destroy blood cells that contain cancer. It’s used ...